We are pleased to share an article titled “The growing role of multi-omics within drug discovery,” published in Drug Discovery News (DDN). Written by Bree Foster, PhD, the article explains how researchers are harnessing multi-omics and AI to transform drug discovery by revealing disease mechanisms, pinpointing therapeutic targets, and speeding up development.
“Today, as the cost of generating multi-omics data continues to fall, the real challenge lies not in collecting the data but in analyzing and making sense of it,” said Juozas Gordevičius, founder of VUGENE.
Each dataset – whether genomic sequences, protein abundances, or metabolite profiles – is often noisy, incomplete, or generated under different experimental conditions.
Real-world applications are already demonstrating the power of this approach. In a recent study published in Critical Care, Michigan State University, Corewell Health, and VUGENE applied longitudinal multi-omics to map the systemic biological response in children following severe traumatic brain injury (TBI). By integrating transcriptomics and metabolomics over multiple time points, the team captured a detailed, dynamic view of the molecular changes that unfold in the days after injury.
“Integrating multiple omics layers can validate promising therapeutic targets and filter out false leads before they derail expensive clinical trials” explained Juozas Gordevičius, founder of VUGENE.
By integrating diverse datasets and applying computational modeling, researchers can identify potential biomarkers and therapeutic targets while also enabling the reconstruction of the dynamic pathways driving disease and recovery.
Bringing these diverse layers together requires more than statistical know-how; it demands a deep understanding of biology, computational methods, and how the two intersect. As researchers push toward precision medicine, finding ways to make sense of complex, multi-layered data is becoming as important as the data itself.
VUGENE democratizes access to powerful multi-omics analysis through a customizable, scalable AI/ML platform. It accelerates therapeutic R&D by combining deep biological insights with scientific expertise and human intelligence – turning large, raw datasets into informed and actionable R&D decisions.
Read full article: Link
Published by: Drug Discovery News on March 30, 2026
Cover photo credits: arrowsmith2 | Adobe Stock
